JP Morgan Chase’s Tonix Pharmaceuticals TNXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $77.9K | Buy |
6,111
+587
| +11% | +$7.58K | ﹤0.01% | 6224 |
|
|
2026
Q1 | $66.5K | Buy |
5,524
+856
| +18% | +$13.2K | ﹤0.01% | 6054 |
|
|
2025
Q4 | $72.9K | Buy |
4,668
+653
| +16% | +$12K | ﹤0.01% | 6065 |
|
|
2025
Q3 | $97K | Buy |
4,015
+439
| +12% | +$16.3K | ﹤0.01% | 5921 |
|
|
2025
Q2 | $129K | Buy |
+3,576
| New | +$93.7K | ﹤0.01% | 5487 |
|
|
2025
Q1 | – | Sell |
-173
| Closed | -$5.7K | – | 7733 |
|
|
2024
Q4 | $5.7K | Buy |
+173
| New | +$3.6K | ﹤0.01% | 6491 |
|
|
2024
Q3 | – | Hold |
0
| – | – | – | 7677 |
|
|
2024
Q2 | – | Hold |
0
| – | – | – | 7236 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 7142 |
|
|
2023
Q4 | – | Sell |
-6
| Closed | -$11.3K | – | 7870 |
|
|
2023
Q3 | $11.3K | Sell |
6
-4
| -40% | -$14.6K | ﹤0.01% | 6222 |
|
|
2023
Q2 | $51.9K | Sell |
10
-5
| -33% | -$37.9K | ﹤0.01% | 5705 |
|
|
2023
Q1 | $173K | Buy |
15
+13
| +650% | +$223K | ﹤0.01% | 5143 |
|
|
2022
Q4 | $19K | Buy |
+2
| New | +$17.3K | ﹤0.01% | 5908 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 6372 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 6892 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 5686 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 5798 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 5312 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 5419 |
|
|
2020
Q4 | – | Hold |
0
| – | -$33K | – | 5931 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 5060 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6053 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 5947 |
|
|
2018
Q3 | – | Hold |
0
| – | -$131K | – | 5827 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 4745 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 5631 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 5577 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 4847 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 5217 |
|
|
2016
Q3 | – | Hold |
0
| – | -$27K | – | 4805 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 4171 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 4941 |
|
Other funds holding TNXP
JHC
JP Morgan Chase's TNXP Position: Q2 2026 in Review
JP Morgan Chase increased its Tonix Pharmaceuticals (TNXP) stake by 11% in Q2 2026, buying an estimated $7.58K and bringing the position to 6,111 shares worth $77.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6224.
JP Morgan Chase first reported a position in TNXP in Q4 2022 and has held it in 10 quarters since. The position peaked at $173K in Q1 2023. 102 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.
- JP Morgan Chase held 6,111 shares of Tonix Pharmaceuticals worth $77.9K as of Q2 2026.
- JP Morgan Chase bought 587 Tonix Pharmaceuticals shares in Q2 2026, an estimated $7.58K.
- Tonix Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6224 holding.
- JP Morgan Chase first reported a position in Tonix Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
- JP Morgan Chase's Tonix Pharmaceuticals position peaked at $173K in Q1 2023.
- 102 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.